Top

Published in:

01-01-2016 | Preclinical study

Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach

Authors: Anton Safonov, Shiyi Wang, Cary P. Gross, Divyansh Agarwal, Giampaolo Bianchini, Lajos Pusztai, Christos Hatzis

Published in: Breast Cancer Research and Treatment | Issue 2/2016

Abstract

Evaluation of cost-utility is critical in assessing the medical utility of predictive or prognostic biomarkers. Current methods involve complex state-transition models, requiring comprehensive data inputs. We propose a simplified decision-analytic tool to explore the relative effect of factors contributing to the cost-utility of a biomarker. We derived a cost-utility metric, the “test incremental cost-effectiveness ratio” (TICER) for biomarker-guided treatment compared to no biomarker use. This method uses data inputs readily accessible through clinical literature. We compared our results with traditional cost-effectiveness analysis of predictive biomarkers for established (HER2-guided trastuzumab, ALK-guided crizotinib, OncotypeDX-guided adjuvant chemotherapy) and emerging (ROS1-guided crizotinib) targeted treatments. We conducted sensitivity analysis to determine which factors had the greatest impact on TICER estimates. Base case TICER for HER2 was $149,600/quality-adjusted life year (QALY), for ALK was $22,200/QALY, and for OncotypeDX was $11,600/QALY, consistent with literature-reported estimates ($180,000/QALY, $202,800/QALY, $8900/QALY, respectively). Base case TICER for ROS1-guided crizotinib was $205,900/QALY. Generally, when treatment cost is considerably greater than biomarker testing costs, TICER is driven by clinical outcomes and health-related quality of life, while biomarker prevalence and treatment cost have a lesser effect. Our simplified decision-analytic approach produces values consistent with existing cost-effectiveness analyses. Our results suggest that biomarker value is mostly driven by the clinical efficacy of the targeted agent. A user-friendly web tool for complete TICER analysis has been made available for open use at http://medicine.yale.edu/lab/pusztai/ticer/.

Available only for authorised users

Scalo JF, Rascati KL (2014) Trends and issues in oncology costs. Expert Rev Pharmacoecon Outcomes Res 14(1):35–44. doi:10.1586/14737167.2014.864561 CrossRefPubMed

Fund C (2008) Why not the best?: results from the National Scorecard on US Health System Performance 2008. Commonwealth Fund, New York

Woolf SH, Aron L (2013) U.S. Health in International perspective: shorter lives, poorer health. In: Woolf SH, Aron L (eds) The National academies collection: reports funded by National Institutes of Health. Institute of Medicine of the National Academies, Washington

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792. doi:10.1056/NEJM200103153441101 CrossRefPubMed

Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528):563–567. doi:10.1038/nature14011 CrossRefPubMed

Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F, Investigators P (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371(23):2167–2177. doi:10.1056/NEJMoa1408440 CrossRefPubMed

Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML (2011) Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst 103(2):117–128. doi:10.1093/jnci/djq495 PubMedCentralCrossRefPubMed

Schnipper LE, Davidson NE, Wollins DS, Tyne C, Blayney DW, Blum D, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, Schrag D, Smith TJ, Yu PP, Hudis CA, Schilsky RL (2015) American Society of Clinical Oncology Statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol. doi:10.1200/JCO.2015.61.6706 PubMed

Mushlin AI, Ruchlin HS, Callahan MA (2001) Cost effectiveness of diagnostic tests. Lancet 358(9290):1353–1355CrossRefPubMed

10.

Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL (2005) Methods for the economic evaluation of health care programmes. OUP Catalogue, Oxford

11.

Garber AM (2000) Advances in cost-effectiveness analysis of health interventions. Handb Health Econ 1:181–221CrossRef

12.

Rochau U, Jahn B, Qerimi V, Burger EA, Kurzthaler C, Kluibenschaedl M, Willenbacher E, Gastl G, Willenbacher W, Siebert U (2014) Decision-analytic modeling studies: an overview for clinicians using multiple myeloma as an example. Crit Rev Oncol Hematol. doi:10.1016/j.critrevonc.2014.12.017 PubMed

13.

Warner KE, Hutton RC (1980) Cost-benefit and cost-effectiveness analysis in health care. Growth and composition of the literature. Med Care 18(11):1069–1084CrossRefPubMed

14.

Stason WB, Weinstein MC (1977) Public-health rounds at the Harvard School of Public Health. Allocation of resources to manage hypertension. N Engl J Med 296(13):732–739. doi:10.1056/NEJM197703312961307 CrossRefPubMed

15.

Bennett WM (1976) Cost-benefit ratio of pretransplant bilateral nephrectomy. JAMA 235(16):1703–1704CrossRefPubMed

16.

Hillner BE (1998) Review of cost-effectiveness assessments of chemotherapy in adjuvant and advanced breast cancer. Anticancer Drugs 9(10):843–847CrossRefPubMed

17.

Earle CC, Chapman RH, Baker CS, Bell CM, Stone PW, Sandberg EA, Neumann PJ (2000) Systematic overview of cost-utility assessments in oncology. J Clin Oncol 18(18):3302–3317PubMed

18.

Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC (2004) HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 22(5):854–863. doi:10.1200/JCO.2004.04.158 CrossRefPubMed

19.

Djalalov S, Beca J, Hoch JS, Krahn M, Tsao M-S, Cutz J-C, Leighl NB (2014) Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non–small-cell lung cancer. J Clin Oncol 32(10):1012–1019CrossRefPubMed

20.

Tsoi DT, Inoue M, Kelly CM, Verma S, Pritchard KI (2010) Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer. Oncologist 15(5):457–465PubMedCentralCrossRefPubMed

21.

Benbassat J, Zajicek G, van Oortmarssen GJ, Ben-Dov I, Eckman MH (1993) Inaccuracies in estimates of life expectancies of patients with bronchial cancer in clinical decision making. Med Decis Mak 13(3):237–244CrossRef

22.

John-Baptiste AA, Bell C (2011) A glimpse into the black box of cost-effectiveness analyses. Can Med Assoc J 183(6):E307–E308CrossRef

23.

Shaw AT, Solomon BJ (2015) Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 372(7):683–684. doi:10.1056/NEJMc1415359 CrossRefPubMed

24.

Detsky AS, Naglie IG (1990) A clinician’s guide to cost-effectiveness analysis. Ann Intern Med 113(2):147–154CrossRefPubMed

25.

Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J (2008) Health state utilities for non small cell lung cancer. Health Qual Life Outcomes 6(84):84PubMedCentralCrossRefPubMed

26.

de Koning HJ, van Ineveld BM, van Oortmarssen GJ, de Haes JC, Collette HJ, Hendriks JH, van der Maas PJ (1991) Breast cancer screening and cost-effectiveness; policy alternatives, quality of life considerations and the possible impact of uncertain factors. Int J Cancer 49(4):531–537CrossRefPubMed

27.

Tengs TO, Wallace A (2000) One thousand health-related quality-of-life estimates. Med care 38:583–637CrossRefPubMed

28.

Vergara-Lluri ME, Moatamed NA, Hong E, Apple SK (2012) High concordance between HercepTest immunohistochemistry and ERBB2 fluorescence in situ hybridization before and after implementation of American Society of Clinical Oncology/College of American Pathology 2007 guidelines. Mod Pathol 25(10):1326–1332. doi:10.1038/modpathol.2012.93 CrossRefPubMed

29.

Fenwick E, Byford S (2005) A guide to cost-effectiveness acceptability curves. Brit J Psychiat 187:106–108. doi:10.1192/bjp.187.2.106 CrossRefPubMed

30.

Hunger M, Doring A, Holle R (2012) Longitudinal beta regression models for analyzing health-related quality of life scores over time. BMC Med Res Methodol 12:144. doi:10.1186/1471-2288-12-144 PubMedCentralCrossRefPubMed

31.

Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky AJ, Stearns V, Winer EP, Griggs JJ (2014) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J clin oncol 32(21):2255–2269. doi:10.1200/JCO.2013.54.2258

32.

Rugo H, Brammer M, Zhang F, Lalla D (2010) Effect of trastuzumab on health-related quality of life in patients with HER2-positive metastatic breast cancer: data from three clinical trials. Clin Breast Cancer 10(4):288–293. doi:10.3816/CBC.2010.n.037

33.

Handorf EA, McElligott S, Vachani A, Langer CJ, Bristol Demeter M, Armstrong K, Asch DA (2012) Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lung. J oncol pract 8(5):267–274. doi:10.1200/JOP.2011.000502

34.

Flanagan MB, Dabbs DJ, Brufsky AM, Beriwal S, Bhargava R (2008) Histopathologic variables predict Oncotype DX recurrence score. Mod pathol 21(10):1255–1261. doi:10.1038/modpathol.2008.54

35.

Hornberger J, Chien R, Krebs K, Hochheiser L (2011) US insurance program's experience with a multigene assay for early-stage breast cancer. J oncol pract 7(3 Suppl):e38s–e45s. doi:10.1200/JOP.2011.000303

36.

Gafni A, Birch S (2006) Incremental cost-effectiveness ratios (ICERs): the silence of the lambda. Soc Sci Med 62(9):2091–2100CrossRefPubMed

37.

Hall PS, McCabe C, Stein RC, Cameron D (2012) Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer. J Natl Cancer Inst 104(1):56–66. doi:10.1093/jnci/djr484 CrossRefPubMed

Title: Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach
Authors: Anton Safonov
Shiyi Wang
Cary P. Gross
Divyansh Agarwal
Giampaolo Bianchini
Lajos Pusztai
Christos Hatzis
Publication date: 01-01-2016
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2016
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-016-3677-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2016

A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer

Choice of study endpoint significantly impacts the results of breast cancer trials evaluating chemotherapy-induced nausea and vomiting

The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl

Telomeric G-quadruplex-forming DNA fragments induce TLR9-mediated and LL-37-regulated invasion in breast cancer cells in vitro

Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines

Silencing overexpression of FXYD3 protein in breast cancer cells amplifies effects of doxorubicin and γ-radiation on Na+/K+-ATPase and cell survival

Keynote webinar | Spotlight on antibody–drug conjugates in cancer